Clinical outcome of epidermal growth factor receptor‐tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations

BACKGROUND: Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the second most common mutated gene following epidermal growth factor receptor (EGFR) mutation in Chinese lung adenocarcinoma (LADC) patients. Investigating the clinical characteristics and outcomes of patients with co‐existing KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hong, Bai, Hua, Yang, Xiaodan, Zhong, Jia, An, Tongtong, Zhao, Jun, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718136/
https://www.ncbi.nlm.nih.gov/pubmed/26813477
http://dx.doi.org/10.1111/1759-7714.12266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718136/
https://www.ncbi.nlm.nih.gov/pubmed/26813477
http://dx.doi.org/10.1111/1759-7714.12266

Ejemplares similares